Amjevita Injection
Product Images NDC 72511-482

83 FDA label images from Amgen Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 83 technical images submitted to the FDA as part of the official labeling for Amjevita (NDC 72511-482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Amjevita Amgenusa 01)

Figure 1 (Amjevita Amgenusa 01)
A line graph showing the percent of ACR 20 responders over time in weeks. Two lines compare response rates: one for 40 mg every other week of adalimumab-atto and one for placebo. The 40 mg treatment line shows a higher and sustained responder percentage compared to placebo over 48 weeks.*
FDA Label Image

Figure 2 (Amjevita Amgenusa 02)

Figure 2 (Amjevita Amgenusa 02)
A line graph comparing the percentage of ASAS 20 response over time (weeks) between two groups: placebo (N=107) and adalimumab (N=208). The adalimumab group's response rises sharply to about 60% by week 8 and then gradually declines to around 50% by week 24. The placebo group's response peaks just above 30% around week 8 and remains relatively stable thereafter.*
FDA Label Image

Figure 3 (Amjevita Amgenusa 03)

Figure 3 (Amjevita Amgenusa 03)
A Kaplan-Meier curve depicting treatment failure rates over time in months for placebo and adalimumab groups. The y-axis shows treatment failure rate in percentage, and the x-axis shows time in months up to 20 months. The solid line represents placebo, showing a higher failure rate, while the dashed line represents adalimumab, showing a lower failure rate over the same period.*
FDA Label Image

Figure 3 (Amjevita Amgenusa 04)

Figure 3 (Amjevita Amgenusa 04)
A line graph illustrating treatment failure rate (%) over time (months) comparing placebo and adalimumab treatments. The x-axis shows time in months up to 20, and the y-axis indicates treatment failure rate percentages from 0 to 100. Two lines represent placebo (solid) and adalimumab (dashed), showing lower failure rates with adalimumab over time.*
FDA Label Image

Figure 4 (Amjevita Amgenusa 05)

Figure 4 (Amjevita Amgenusa 05)
This is a Kaplan-Meier curve displaying the probability of failing treatment over time in weeks, comparing adalimumab and placebo. The solid line represents adalimumab treatment, and the dashed line represents placebo. The y-axis indicates the probability of failing treatment, and the x-axis shows the time in weeks, with numbers at risk for each group noted below.*
FDA Label Image

Image (Amjevita Amgenusa 06)

Image (Amjevita Amgenusa 06)
Illustration of a 40 mg/0.8 mL AMJEVITA (adalimumab-atto) subcutaneous injection pen. The pen is blue with a yellow safety guard cap covering the needle. It features a light blue start button at the top, a window displaying the medicine and plunger, and labeled areas for the expiration date and cream safety guard.*
FDA Label Image

Image (Amjevita Amgenusa 07)

Image (Amjevita Amgenusa 07)
An instructional illustration showing a folded carton with an arrow pointing to it, accompanied by the text 'Refrigerate in carton until ready to use.' This diagram indicates proper storage instructions for the product AMJEVITA injection.*
FDA Label Image

Image (Amjevita Amgenusa 08)

Image (Amjevita Amgenusa 08)
An illustration of a clock face marked with incremental tick marks and the text '15-30 minutes' centered inside. It likely indicates a time duration or waiting period related to the product usage or instructions.*
FDA Label Image

Image (Amjevita Amgenusa 09)

Image (Amjevita Amgenusa 09)
Illustration of a calendar page showing "14 days," likely indicating a two-week interval for dosing or treatment schedule for AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita Amgenusa 10)

Image (Amjevita Amgenusa 10)
An instructional diagram showing an AMJEVITA injection pen with a close-up highlighting the medicine window, indicating the presence of medicine within the device. The pen is primarily blue and black with a yellow base.*
FDA Label Image

Image (Amjevita Amgenusa 11)

Image (Amjevita Amgenusa 11)
An instructional illustration showing an injection pen with a highlighted section focusing on the location of the lot number and expiration date on the device or its packaging.*
FDA Label Image

Image (Amjevita Amgenusa 12)

Image (Amjevita Amgenusa 12)
An instructional illustration showing a red sharps disposal container with a flip-top lid. Next to it are labeled items for injection cleanup: an alcohol wipe, an adhesive bandage, and cotton balls or gauze pads. This diagram supports proper disposal and post-injection care for subcutaneous injections.*
FDA Label Image

Image (Amjevita Amgenusa 13)

Image (Amjevita Amgenusa 13)
An anatomical illustration showing recommended subcutaneous injection sites on a human figure. Highlighted areas include the abdomen and the front of the thighs, indicating common locations for administering subcutaneous injections.*
FDA Label Image

Image (Amjevita Amgenusa 14)

Image (Amjevita Amgenusa 14)
An instructional illustration showing two hands washing. One hand is rubbing the back of the other hand, with small bubbles indicating soap or cleanser, demonstrating a handwashing technique.*
FDA Label Image

Image (Amjevita Amgenusa 15)

Image (Amjevita Amgenusa 15)
An instructional illustration showing a hand pressing down on a small rectangular alcohol prep pad, indicating the step of cleaning the skin prior to injection.*
FDA Label Image

Image (Amjevita Amgenusa 16)

Image (Amjevita Amgenusa 16)
Instructional illustration showing a hand holding an AMJEVITA injection pen and another hand removing or holding the yellow cap, with an arrow indicating that the window on the pen should be visible before use.*
FDA Label Image

Image (Amjevita Amgenusa 17)

Image (Amjevita Amgenusa 17)
An instructional illustration showing the technique for administering AMJEVITA (adalimumab-atto) subcutaneous injection. The image depicts a hand holding the injection pen perpendicular to the skin at the injection site, with the other hand pinching the skin to prepare for injection.*
FDA Label Image

Image (Amjevita Amgenusa 18)

Image (Amjevita Amgenusa 18)
Instructional diagram showing the use of an injection device. The illustration depicts a hand pressing down on a device with an arrow indicating downward motion, followed by a second image showing the device in position for injection, suggesting steps for administering a subcutaneous injection.*
FDA Label Image

Image (Amjevita Amgenusa 19)

Image (Amjevita Amgenusa 19)
An instructional illustration showing a hand gripping the top of a device, with a downward-pointing arrow above the hand, indicating pressing or pushing action. No text or product branding is visible in the image.*
FDA Label Image

Image (Amjevita Amgenusa 20)

Image (Amjevita Amgenusa 20)
An instructional illustration demonstrating how to use a subcutaneous injection pen. The first part shows a hand holding the pen pressing it downward against the skin. The following images depict a window on the pen showing a color change from white to yellow, indicating the injection progress and completion.*
FDA Label Image

Image (Amjevita Amgenusa 21)

Image (Amjevita Amgenusa 21)
An instructional illustration depicting the removal of a yellow needle cap from a blue and yellow AMJEVITA injection pen, shown with its cap removed and an arrow indicating the needle cap being detached from the injection device.*
FDA Label Image

Image (Amjevita Amgenusa 22)

Image (Amjevita Amgenusa 22)
An illustration showing one adhesive bandage above three pieces of cotton balls or wads of cotton. The bandage has a rectangular pad in the center with three small ventilation holes on each side.*
FDA Label Image

Image (Amjevita Amgenusa 23)

Image (Amjevita Amgenusa 23)
Illustration of an AMJEVITA 40 mg/0.4 mL subcutaneous injection pen showing labeled parts including expiration date, light blue start button, plunger visible through a window, medicine inside the pen, a cream safety guard covering the needle, and a yellow cap at the base.*
FDA Label Image

Image (Amjevita Amgenusa 24)

Image (Amjevita Amgenusa 24)
An instructional diagram showing a carton with an arrow pointing to it and the text 'Refrigerate in carton until ready to use,' indicating storage instructions for the product packaging.*
FDA Label Image

Image (Amjevita Amgenusa 25)

Image (Amjevita Amgenusa 25)
A circular timer illustration showing the time range "15-30 minutes" displayed prominently in the center, likely indicating a waiting or observation period relevant to the medication usage instructions.*
FDA Label Image

Image (Amjevita Amgenusa 26)

Image (Amjevita Amgenusa 26)
An illustration of a calendar page showing the number 14 prominently, with the word "days" below it, suggesting a 14-day interval or schedule reminder.*
FDA Label Image

Image (Amjevita Amgenusa 27)

Image (Amjevita Amgenusa 27)
An instructional illustration showing a blue and yellow pen-style injector for AMJEVITA (adalimumab-atto) injection. A zoomed inset highlights the medicine window on the injector, labeled "Medicine," showing the liquid inside. The image demonstrates a key feature of the injection device for subcutaneous use.*
FDA Label Image

Image (Amjevita Amgenusa 28)

Image (Amjevita Amgenusa 28)
An illustration showing a blue injection pen with a close-up of its label window highlighting the locations for the lot number and expiration date. The image indicates where to find the expiration date on the pen for AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita Amgenusa 29)

Image (Amjevita Amgenusa 29)
An instructional illustration showing a sharps disposal container with labels identifying three medical supplies beside it: an alcohol wipe, an adhesive bandage, and a cotton ball or gauze pad. The image is intended to guide safe disposal and post-injection care materials.*
FDA Label Image

Image (Amjevita Amgenusa 30)

Image (Amjevita Amgenusa 30)
Illustration showing recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto). The highlighted areas on the body include the abdomen, front thighs, and upper outer arms, indicating appropriate locations for injection administration.*
FDA Label Image

Image (Amjevita Amgenusa 31)

Image (Amjevita Amgenusa 31)
A black and white line drawing showing two hands washing with soap bubbles, illustrating handwashing or hygiene practice.*
FDA Label Image

Image (Amjevita Amgenusa 32)

Image (Amjevita Amgenusa 32)
An instructional illustration showing a hand pressing a swab or wipe onto a surface, likely demonstrating disinfection or cleaning technique for preparing an injection site or medical surface.*
FDA Label Image

Image (Amjevita Amgenusa 33)

Image (Amjevita Amgenusa 33)
An instructional illustration showing proper handling of an AMJEVITA (adalimumab-atto) injection pen. The image depicts a hand holding the injection pen and another hand removing or placing a yellow cap, with an arrow and text indicating that the window on the pen should be visible before use.*
FDA Label Image

Image (Amjevita Amgenusa 34)

Image (Amjevita Amgenusa 34)
An instructional illustration depicting a hand holding a pen-style injector for subcutaneous injection. The diagram shows the user pinching the skin at the injection site, demonstrating proper injection technique.*
FDA Label Image

Image (Amjevita Amgenusa 35)

Image (Amjevita Amgenusa 35)
Instructional diagram showing two steps for using a device: positioning the device tip downward toward the skin, followed by pressing it firmly to administer an injection. The illustrations emphasize proper orientation and application technique for a subcutaneous injection device.*
FDA Label Image

Image (Amjevita Amgenusa 36)

Image (Amjevita Amgenusa 36)
An instructional illustration showing a hand gripping a black device with a blue top, with a downward arrow above the hand indicating a pressing or pushing action.*
FDA Label Image

Image (Amjevita Amgenusa 37)

Image (Amjevita Amgenusa 37)
An instructional diagram showing the use of a subcutaneous injection pen. The illustration depicts pressing the pen into the skin and shows a close-up of the injection window indicating the injection progress or completion.*
FDA Label Image

Image (Amjevita Amgenusa 38)

Image (Amjevita Amgenusa 38)
An instructional illustration showing the use of an injection pen near an open container with a flip-top lid. The diagram features a blue arrow indicating to open or access the container. A yellow cap or needle cover is also depicted separately, emphasizing preparation steps for subcutaneous injection.*
FDA Label Image

Image (Amjevita Amgenusa 39)

Image (Amjevita Amgenusa 39)
An illustration showing a beige adhesive bandage with four holes on each side and a rectangular pad in the center, positioned above three cotton balls. The image likely represents supplies or tools related to subcutaneous injection procedures.*
FDA Label Image

Image (Amjevita Amgenusa 40)

Image (Amjevita Amgenusa 40)
An instructional diagram of an AMJEVITA 80 mg/0.8 mL subcutaneous injection pen by Amgen USA Inc. The diagram labels key pen components including the light blue start button, expiration date window, medicine window showing the plunger, cream safety guard containing the needle, and the yellow cap at the pen tip.*
FDA Label Image

Image (Amjevita Amgenusa 41)

Image (Amjevita Amgenusa 41)
Illustration showing a carton with an arrow pointing inside it, accompanied by the instruction to refrigerate the carton until ready to use, indicating proper storage guidance for AMJEVITA injection.*
FDA Label Image

Image (Amjevita Amgenusa 42)

Image (Amjevita Amgenusa 42)
An illustration of a clock face showing the time interval of 15 to 30 minutes, indicated by text inside the clock circle. The clock has simple tick marks but no hands, emphasizing the specified time range.*
FDA Label Image

Image (Amjevita Amgenusa 43)

Image (Amjevita Amgenusa 43)
An illustration of a calendar page icon showing "14 days". This image likely represents a time interval or schedule related to the product AMJEVITA, an adalimumab-atto subcutaneous injection by Amgen USA Inc.*
FDA Label Image

Image (Amjevita Amgenusa 44)

Image (Amjevita Amgenusa 44)
An instructional illustration showing a blue and yellow prefilled injection pen for AMJEVITA (adalimumab-atto). A close-up view highlights the medicine window, labeled to indicate where the medicine is visible within the pen. The diagram is intended to guide users on locating the medicine inside the device.*
FDA Label Image

Image (Amjevita Amgenusa 45)

Image (Amjevita Amgenusa 45)
An instructional diagram showing a blue and yellow injectable pen for AMJEVITA (adalimumab-atto) subcutaneous injection. The image highlights the location of the lot number and expiration date on the pen's label for user reference.*
FDA Label Image

Image (Amjevita Amgenusa 46)

Image (Amjevita Amgenusa 46)
An instructional illustration showing a sharps disposal container alongside labeled components used for injection: an alcohol wipe, an adhesive bandage, and a cotton ball or gauze pad. The container is red with a white lid and opening for safe disposal of needles or sharps.*
FDA Label Image

Image (Amjevita Amgenusa 47)

Image (Amjevita Amgenusa 47)
An instructional diagram depicting preferred subcutaneous injection sites for AMJEVITA (adalimumab-atto). Highlighted areas include the abdomen around the navel and the front thighs. The human figure shows these injection areas in blue to guide patients on suitable locations for administering the injection.*
FDA Label Image

Image (Amjevita Amgenusa 48)

Image (Amjevita Amgenusa 48)
An instructional illustration showing two hands washing with soap bubbles, indicating proper hand hygiene or handwashing technique.*
FDA Label Image

Image (Amjevita Amgenusa 49)

Image (Amjevita Amgenusa 49)
An instructional illustration showing a hand pressing down on a small adhesive pad, likely demonstrating how to apply or secure a patch or dressing to the skin. No text or product-specific details are visible.*
FDA Label Image

Image (Amjevita Amgenusa 50)

Image (Amjevita Amgenusa 50)
An instructional illustration showing a hand holding an AMJEVITA (adalimumab-atto) prefilled pen injection device and another hand holding the yellow cap. The blue arrow points to the yellow cap, indicating that the window on the injection device should be visible before administration, demonstrating proper handling before injection.*
FDA Label Image

Image (Amjevita Amgenusa 51)

Image (Amjevita Amgenusa 51)
Illustration showing the proper technique for administering AMJEVITA (adalimumab-atto) injection subcutaneously. The image depicts a hand holding the injection pen perpendicular to the skin, with the other hand pinching the skin at the injection site to prepare for injection.*
FDA Label Image

Image (Amjevita Amgenusa 52)

Image (Amjevita Amgenusa 52)
Instructional illustration showing how to prepare or use the AMJEVITA injection pen, with two panels depicting pressing and positioning the pen for subcutaneous injection. The images emphasize correct handling technique without text.*
FDA Label Image

Image (Amjevita Amgenusa 53)

Image (Amjevita Amgenusa 53)
An instructional illustration showing a hand gripping a medication pen with a downward arrow above it, indicating the step of pressing or activating the injector for a subcutaneous injection, related to AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita Amgenusa 54)

Image (Amjevita Amgenusa 54)
An instructional illustration showing the use of a pen-style injection device for subcutaneous administration. It depicts a hand pressing the pen into the skin and a close-up of the device indicating visual cues for proper injection, likely related to the medication AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita Amgenusa 55)

Image (Amjevita Amgenusa 55)
An instructional illustration showing a yellow cap being removed from a blue pen-type injection device, positioned next to an open container with a white interior. A blue arrow indicates the action of placing the pen into the container, suggesting storage or preparation steps for the injection device used with AMJEVITA (adalimumab-atto) subcutaneous injection.*
FDA Label Image

Image (Amjevita Amgenusa 56)

Image (Amjevita Amgenusa 56)
An illustration showing a rectangular adhesive bandage with rounded corners and multiple small circular holes at both ends, alongside three white, irregularly shaped cotton balls.*
FDA Label Image

Image (Amjevita Amgenusa 57)

Image (Amjevita Amgenusa 57)
An instructional diagram of a subcutaneous injection syringe showing labeled parts including the plunger rod, finger grip, expiration date, syringe body, plunger position (variable), medicine inside the barrel, and needle cap covering the needle. The syringe is consistent with injection devices used for products like AMJEVITA adalimumab-atto.*
FDA Label Image

Image (Amjevita Amgenusa 58)

Image (Amjevita Amgenusa 58)
An illustrated diagram of a subcutaneous injection device, likely representing the delivery mechanism for AMJEVITA (adalimumab-atto) injection. The device shows the plunger, barrel, and needle cover components in a vertical layout designed for self-administration.*
FDA Label Image

Image (Amjevita Amgenusa 59)

Image (Amjevita Amgenusa 59)
An illustration of a syringe device, featuring a blue plunger, a white handle, and a clear barrel with measurement markings, used for subcutaneous injection of AMJEVITA (adalimumab-atto). The image shows the syringe in a vertical orientation, ready for use.*
FDA Label Image

Image (Amjevita Amgenusa 60)

Image (Amjevita Amgenusa 60)
An illustration of a pre-filled syringe designed for subcutaneous injection. The syringe shows a cylindrical barrel with a plunger and an orange needle cap, indicating a medical injection device likely associated with AMJEVITA (adalimumab-atto) therapy.*
FDA Label Image

Image (Amjevita Amgenusa 61)

Image (Amjevita Amgenusa 61)
Instructional diagram showing a carton with a flap open and an arrow pointing to it, accompanied by the text 'Refrigerate in carton until ready to use.' This indicates storage instructions for AMJEVITA injection.*
FDA Label Image

Image (Amjevita Amgenusa 62)

Image (Amjevita Amgenusa 62)
An instructional illustration showing a hand holding an AMJEVITA prefilled syringe. A close-up highlights the thumb pushing up the plunger of the syringe, demonstrating the injection or medication delivery step from the packaging box.*
FDA Label Image

Image (Amjevita Amgenusa 63)

Image (Amjevita Amgenusa 63)
An illustration of a clock face displaying the time interval '15-30 minutes' prominently in the center, indicating a time duration or waiting period.*
FDA Label Image

Image (Amjevita Amgenusa 64)

Image (Amjevita Amgenusa 64)
An illustration of a calendar page showing the number 14 and the word "days" underneath, representing a two-week time period.*
FDA Label Image

Image (Amjevita Amgenusa 65)

Image (Amjevita Amgenusa 65)
An instructional illustration showing a red sharps disposal container with an open lid, labeled for safe discarding of needles. To the right, labeled images of an alcohol wipe, adhesive bandage, and cotton ball or gauze pad are shown as supplies related to injection site care for subcutaneous injections.*
FDA Label Image

Image (Amjevita Amgenusa 66)

Image (Amjevita Amgenusa 66)
An instructional illustration showing a syringe design with a close-up view of the lower part of the syringe barrel where the medicine is contained. The labeled section highlights the medicine inside the syringe, indicating the portion intended for injection.*
FDA Label Image

Image (Amjevita Amgenusa 67)

Image (Amjevita Amgenusa 67)
An instructional diagram showing a subcutaneous injection syringe labeled AMJEVITA (adalimumab-atto). The illustration highlights the location on the syringe where the expiration date is displayed.*
FDA Label Image

Image (Amjevita Amgenusa 68)

Image (Amjevita Amgenusa 68)
Illustration showing recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto). Highlighted areas include the abdomen around the navel and the front of the thighs, indicating proper locations for administering the injection.*
FDA Label Image

Image (Amjevita Amgenusa 69)

Image (Amjevita Amgenusa 69)
An instructional illustration showing two hands washing with soap lather and bubbles. This diagram likely demonstrates proper handwashing technique to ensure cleanliness.*
FDA Label Image

Image (Amjevita Amgenusa 70)

Image (Amjevita Amgenusa 70)
An instructional illustration showing a hand pressing down on the top of a vial or similar small container, likely demonstrating how to activate or open the product preparation prior to subcutaneous injection. No visible text or labels are present in the image.*
FDA Label Image

Image (Amjevita Amgenusa 71)

Image (Amjevita Amgenusa 71)
Illustration showing hands preparing a prefilled syringe for subcutaneous injection. The left hand holds the syringe cap while the right hand is positioned to remove the cap from the syringe, indicated by a blue arrow pointing left.*
FDA Label Image

Image (Amjevita Amgenusa 72)

Image (Amjevita Amgenusa 72)
An instructional diagram showing the top of a container with its lid open, alongside an object with an arrow indicating insertion into the container. The illustration likely depicts a step in preparing or using the medication AMJEVITA injection by subcutaneous route.*
FDA Label Image

Image (Amjevita Amgenusa 73)

Image (Amjevita Amgenusa 73)
Illustration showing a hand pinching the skin at an injection site on the arm, demonstrating preparation for a subcutaneous injection.*
FDA Label Image

Image (Amjevita Amgenusa 74)

Image (Amjevita Amgenusa 74)
An instructional diagram illustrating the subcutaneous injection technique for AMJEVITA (adalimumab-atto). It shows a hand holding a syringe at a 45-degree angle to the skin on the other hand, with a blue arrow indicating the injection direction.*
FDA Label Image

Image (Amjevita Amgenusa 75)

Image (Amjevita Amgenusa 75)
An instructional illustration showing a hand administering a subcutaneous injection with a syringe into the skin of an arm or hand. A blue arrow indicates the direction of needle insertion. The image demonstrates proper injection technique.*
FDA Label Image

Image (Amjevita Amgenusa 76)

Image (Amjevita Amgenusa 76)
An instructional illustration showing a hand holding a syringe poised to inject into a vial with its cap partially lifted, indicated by a blue arrow pointing downward towards the vial opening. This image likely demonstrates the step of inserting a syringe needle into a vial for drug withdrawal.*
FDA Label Image

Image (Amjevita Amgenusa 77)

Image (Amjevita Amgenusa 77)
Illustration showing a beige adhesive bandage centered above three white cotton balls, likely depicting basic wound care supplies or materials associated with injection site care.*
FDA Label Image

Principal Display Panel (40 mg/0.8 mL Autoinjector Carton)

Principal Display Panel (40 mg/0.8 mL Autoinjector Carton)
AMJEVITA 40 mg/0.8 mL injection prefilled autoinjector label showing adalimumab-atto as the active ingredient. The label indicates subcutaneous use only, sterile solution with no preservative, refrigerated storage at 2°C to 8°C, and cautions to protect from light and avoid freezing or shaking. It notes the product is not made with natural rubber latex and contains one single-dose prefilled autoinjector. Manufactured by Amgen USA Inc.*
FDA Label Image

Principal Display Panel (40 mg/0.4 mL Autoinjector Carton)

Principal Display Panel (40 mg/0.4 mL Autoinjector Carton)
AMJEVITA 40 mg/0.4 mL injection for subcutaneous use by Amgen USA Inc. The packaging features a blue and yellow design with a single-dose prefilled SureClick autoinjector illustration. The label includes storage instructions to refrigerate at 2°C to 8°C, warnings to not freeze, shake, or reuse, and states the product contains no preservative or natural rubber latex.*
FDA Label Image

Principal Display Panel (Two 40 mg/0.4 mL Autoinjector Carton)

Principal Display Panel (Two 40 mg/0.4 mL Autoinjector Carton)
AMJEVITA 40 mg/0.4 mL injection by Amgen USA Inc. This packaging label shows a sterile solution of adalimumab-atto for subcutaneous use only, featuring 2 single-dose prefilled SureClick autoinjectors. Storage instructions include refrigeration at 2°C to 8°C, no freezing, no shaking, and protection from light. The label notes the product is not made with natural rubber latex.*
FDA Label Image

Principal Display Panel (20 mg/0.2 mL Syringe Carton)

Principal Display Panel (20 mg/0.2 mL Syringe Carton)
AMJEVITA 20 mg/0.2 mL injection, subcutaneous single-dose prefilled syringe by Amgen USA Inc. The label indicates storage refrigerated at 2°C to 8°C, sterile solution with no preservative, and notes it is not made with natural rubber latex. Packaging also highlights use in pediatric patients 15 to <30 kg and requires an enclosed medication guide.*
FDA Label Image

Principal Display Panel (40 mg/0.4 mL Syringe Carton)

Principal Display Panel (40 mg/0.4 mL Syringe Carton)
AMJEVITA 40 mg/0.4 mL injection packaging label shows a subcutaneous injection dosage form. The label includes 2 single-dose prefilled syringes, instructions to refrigerate until ready to use, and warnings not to use if the carton seal is broken. Manufactured by Amgen USA Inc., it specifies no preservatives and storage temperature between 2°C to 8°C. The label also indicates the product is not made with natural rubber latex.*
FDA Label Image

Principal Display Panel (80 mg/0.8 mL Autoinjector Carton)

Principal Display Panel (80 mg/0.8 mL Autoinjector Carton)
AMJEVITA 80 mg/0.8 mL subcutaneous injection by Amgen USA Inc. The label shows two single-dose prefilled SureClick autoinjectors. This sterile solution contains no preservatives and must be refrigerated at 2°C to 8°C (36°F to 46°F), not frozen or shaken. The product is for subcutaneous use only and not made with natural rubber latex. The label includes storage and caution information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.